Research Center on Thromboembolic Diseases and Antithrombotic Therapies, Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Blood Rev. 2023 Nov;62:101119. doi: 10.1016/j.blre.2023.101119. Epub 2023 Aug 10.
Anticoagulant drugs that are currently used to prevent and/or treat thrombosis have some limitations that hinder their ability to meet specific clinical requirements. While these drugs effectively reduce the rates of thrombotic events, they simultaneously increase the risk of bleeding. Moreover, their risk-to-benefit balance is problematic in some patients, such as those with severe chronic kidney disease or those at high bleeding risk. A novel anticoagulation method, FXI inhibition has emerged as a promising alternative. It demonstrates a strong rationale for the prevention and treatment of venous thromboembolism and the potential fulfillment of unmet clinical needs in the cardiovascular field. A number of FXI inhibitors are currently undergoing clinical investigation. The objective of this review is to provide an overview of early results of research on FXI inhibitors in the cardiovascular setting, offering valuable insights into their potential role in shaping the future of anticoagulation.
目前用于预防和/或治疗血栓形成的抗凝药物存在一些局限性，阻碍了它们满足特定临床需求的能力。虽然这些药物能有效降低血栓事件的发生率，但同时也增加了出血的风险。此外，在某些患者中，如患有严重慢性肾脏疾病或出血风险高的患者，其风险效益平衡存在问题。一种新型抗凝方法 FXI 抑制已成为一种有前途的替代方法。它为静脉血栓栓塞的预防和治疗提供了强有力的理论依据，并有可能满足心血管领域未满足的临床需求。目前有几种 FXI 抑制剂正在进行临床研究。本综述的目的是提供 FXI 抑制剂在心血管环境中研究的早期结果概述，为其在塑造抗凝未来方面的潜在作用提供有价值的见解。
